Placenta
Volume 29, Issue 2 , Pages 193-200 , February 2008

Placental 11β-Hydroxysteroid Dehydrogenase Type 2 is Reduced in Pregnancies Complicated with Idiopathic Intrauterine Growth Restriction: Evidence That This is Associated With an Attenuated Ratio of Cortisone to Cortisol in the Umbilical Artery

  • J. Dy
    • ,
  • H. Guan
    • ,
  • R. Sampath-Kumar
    • ,
  • B.S. Richardson
    • ,
  • K. Yang

      Affiliations

    • Corresponding Author InformationCorresponding author at: Children's Health Research Institute, Room A5-132, Victoria Research Laboratories, Westminster Campus, 800 Commissioners Road East, London, Ontario N6C 6B5, Canada. Tel.: +1 519 685 8500x55069; fax: +1 519 685 8186.

,Accepted 25 October 2007.

References 

  1. Lin CC, Santolaya-Forgas J. Current concepts of fetal growth restriction: part I. Causes, classification, and pathophysiology. Obstet Gynecol. 1998;92:1044–1055
  2. Brodsky D, Christou H. Current concepts in intrauterine growth restriction. J Intensive Care Med. 2004;19:307–319
  3. Cetin I, Foidart JM, Miozzo M, Raun T, Jansson T, Tsatsaris V, et al. Fetal growth restriction: a workshop report. Placenta. 2004;25:753–757
  4. Ergaz Z, Avgil M, Ornoy A. Intrauterine growth restriction-etiology and consequences: what do we know about the human situation and experimental animal models?. Reprod Toxicol. 2005;20:301–322
  5. Barker DJ. Growth in utero and coronary heart disease. Nutr Rev. 1996;54:S1–S7
  6. Osmond C, Barker DJ. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect. 2000;108:545–553
  7. Gagnon R. Placental insufficiency and its consequences. Eur J Obstet Gynecol Reprod Biol. 2003;110:S99–S107
  8. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995;9:1608–1621
  9. Seckl JR. Glucocorticoids and small babies. Q J Med. 1994;87:259–262
  10. Seckl JR. Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol. 2001;185:61–71
  11. Yang K. Placental 11 beta-hydroxysteroid dehydrogenase: barrier to maternal glucocorticoids. Rev Reprod. 1997;2:129–132
  12. Burton PJ, Waddell BJ. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod. 1999;60:234–240
  13. Seckl JR, Meaney MJ. Glucocorticoid programming. Ann N Y Acad Sci. 2004;1032:63–84
  14. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet. 1993;341:339–341
  15. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf). 1997;46:161–166
  16. Campbell AL, Murphy BEP. The maternal-fetal cortisol gradient during pregnancy and delivery. J Clin Endocrinol Metabol. 1977;45:435–440
  17. Krozowski Z, MaGuire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab. 1995;80:2203–2209
  18. Pepe GJ, Burch MG, Albrecht ED. Expression of the 11beta-hydroxysteroid dehydrogenase types 1 and 2 proteins in human and baboon placental syncytiotrophoblast. Placenta. 1999;20:575–582
  19. Stewart PM, Rogerson FM, Mason JI. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab. 1995;80:885–890
  20. Murphy VE, Zakar T, Smith R, Giles WB, Gibson PG, Clifton VL. Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma. J Clin Endocrinol Metab. 2002;87:1660–1668
  21. Rogerson FM, Kayes KM, White PC. Variation in placental type 2 11beta-hydroxysteroid dehydrogenase activity is not related to birth weight or placental weight. Mol Cell Endocrinol. 1997;128:103–109
  22. Kitanaka S, Tanae A, Hibi I. Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Clin Endocrinol (Oxf). 1996;44:353–359
  23. Shams M, Kilby MD, Somerset DA, Howie AJ, Gupta A, Wood PJ, et al. 11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod. 1998;13:799–804
  24. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab. 2001;86:4979–4983
  25. Struwe E, Berzl GM, Schild RL, Beckmann MW, Dorr HG, Rascher W, et al. Simultaneously reduced gene expression of cortisol-activating and cortisol-inactivating enzymes in placentas of small-for-gestational-age neonates. Am J Obstet Gynecol. 2007;197(43):e41–e46
  26. McCalla CO, Nacharaju VL, Muneyyirci-Delale O, Glasgow S, Feldman JG. Placental 11 beta-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies. Steroids. 1998;63:511–515
  27. Schoof E, Girstl M, Frobenius W, Kirschbaum M, Dorr HG, Rascher W, et al. Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab. 2001;86:1313–1317
  28. Yang K, Julan L, Rubio F, Sharma A, Guan H. Cadmium reduces 11 beta-hydroxysteroid dehydrogenase type 2 activity and expression in human placental trophoblast cells. Am J Physiol Endocrinol Metab. 2006;290:E135–E142
  29. Julan L, Guan H, van Beek JP, Yang K. Peroxisome proliferator-activated receptor {delta} suppresses 11{beta}-hydroxysteroid dehydrogenase type 2 gene expression in human placental trophoblast cells. Endocrinology. 2005;146:1482–1490Epub 2004 Dec 1489
  30. Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology. 1991;181:129–133
  31. Arbuckle TE, Wilkins R, Sherman GJ. Birth weight percentiles by gestational age in Canada. Obstet Gynecol. 1993;81:39–48
  32. Gratton RJ, Gluszynski M, Mazzuca DM, Nygard K, Han VK. Adrenomedullin messenger ribonucleic acid expression in the placentae of normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2003;88:6048–6055
  33. Yang K. Co-expression of two distinct isoforms of 11 beta-hydroxysteroid dehydrogenase in the ovine placenta. J Steroid Biochem Mol Biol. 1995;52:337–343
  34. Kajantie E, Dunkel L, Turpeinen U, Stenman UH, Wood PJ, Nuutila M, et al. Placental 11 beta-hydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants. J Clin Endocrinol Metab. 2003;88:493–500
  35. van Beek JP, Guan H, Julan L, Yang K. Glucocorticoids stimulate the expression of 11{beta}-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells. J Clin Endocrinol Metab. 2004;89:5614–5621
  36. Yang K, Smith CL, Dales D, Hammond GL, Challis JR. Cloning of an ovine 11 beta-hydroxysteroid dehydrogenase complementary deoxyribonucleic acid: tissue and temporal distribution of its messenger ribonucleic acid during fetal and neonatal development. Endocrinology. 1992;131:2120–2126
  37. Pokoly TB. The role of cortisol in human parturition. Am J Obstet Gynecol. 1973;117:549–554
  38. Smith ID, Shearman RP. Fetal plasma steroids in relation to parturition. The effect of gestational age upon umbilical plasma corticosteroid levels following vaginal delivery. J Obstet Gynaecol Br Commonw. 1974;81:11–15
  39. Leong MKH. Pearson Murphy BE. Cortisol levels in maternal venous and umbilical cord arterial and venous serum at vaginal delivery. Am J Obstet Gynecol. 1976;124:471–473
  40. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest. 1988;82:340–349
  41. Goland RS, Jozak S, Warren WB, Conwell IM, Stark RI, Tropper PJ. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab. 1993;77:1174–1179
  42. Bro-Rasmussen F, Buns O, Trolle D. Ratio cortisone/cortisol in mother and infant at birth. Acta Endocrinol. 1962;40:579–583
  43. Hillman DA, Giroud CJP. Plasma cortisone and cortisol levels at birth and during the neonatal period. J Clin Endocrinol. 1965;25:243–248
  44. Stewart PM, Murry BA, Mason JI. Type 2 11 beta-hydroxysteroid dehydrogenase in human fetal tissues. J Clin Endocrinol Metab. 1994;78:1529–1532
  45. Waddell BJ, Albrecht ED, Pepe GJ. Effect of estrogen on the metabolism of cortisol and cortisone in the baboon fetus at midgestation. Biol Reprod. 1988;38:1006–1011
  46. Hardy DB, Pereria LE, Yang K. Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. Biol Reprod. 1999;61:40–45
  47. Hardy DB, Yang K. The expression of 11 beta-hydroxysteroid dehydrogenase type 2 is induced during trophoblast differentiation: effects of hypoxia. J Clin Endocrinol Metab. 2002;87:3696–3701

PII: S0143-4004(07)00259-7

doi: 10.1016/j.placenta.2007.10.010

Placenta
Volume 29, Issue 2 , Pages 193-200 , February 2008

Article Tools

* Image Usage & Resolution